ConductScience.org, home

Gene · 57124

CD248: CD248 molecule

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. CD248: CD248 molecule. Genes, record 57124. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/57124

On this page

Gene

Symbol
CD248
HGNC
Name
CD248 molecule
HGNC
NCBI Gene ID
57124
NCBI Gene
HGNC ID
HGNC:18219
HGNC
Ensembl
ENSG00000174807
NCBI Gene
Aliases
CD164L1, TEM1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9HCU0Endosialin7570Ensembl, GeneID, HGNC

Source UniProt

Patents94

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1440510Q9HCU0Espacenet
EP 4650780 A22025-11-194538Q9HCU0Espacenet
EP 4641202 A22025-10-29237Q9HCU0Espacenet
EP 4641203 A22025-10-29147Q9HCU0Espacenet
JP 2025529142 A2025-09-04794Q9HCU0Espacenet
US 12371689 B22025-07-29794Q9HCU0Espacenet
JP 2025517967 A2025-06-12147Q9HCU0Espacenet
JP 2025517970 A2025-06-124538Q9HCU0Espacenet
US 12297276 B22025-05-131Q9HCU0Espacenet
JP 2025061086 A2025-04-105Q9HCU0Espacenet

1 to 10 of 94

See all 94 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
ONTUXIZUMABCHEMBL2364659Endosialin inhibitorINHIBITOR

Source ChEMBL

Trials5

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT01773434ONTUXIZUMABPHASE1ClinicalTrials.gov
NCT01748721ONTUXIZUMABPHASE1ClinicalTrials.gov
NCT01574716ONTUXIZUMABPHASE22019-08-21ClinicalTrials.gov
NCT01507545ONTUXIZUMABPHASE22022-05-06ClinicalTrials.gov
NCT01335009ONTUXIZUMABPHASE22021-09-01ClinicalTrials.gov

NIH grants914

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleCD248 papersNewest fiscal year
R01AI032956BETA LACTAMASE MUTATIONS IN ANTIBIOTIC RESISTANCE282025
P30CA008748Cancer Center Support Grant62025
P30CA014051Cancer Center Support (Core) Grant42025
P30CA016520Abramson Cancer Center Support Grant32025
P51OD011106Wisconsin National Primate Research Center Support32025
R35GM133631Characterizing the Effects of Sequence Variability in Molecular Function, Evolution and Design32025
T32AI055449Molecular Basis of Infectious Diseases Training Grant32025
P30CA006973Regional Oncology Research Center22025
P30CA015083Mayo Clinic Comprehensive Cancer Center Support Grant22025
P30CA016058Cancer Center Support Grant22025

1 to 10 of 914Source NIH's project files

See all 914 nih grants

Papers1,901

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Correlation analysis of serum PACAP-38, fibulin-3 and TEM1 levels with cardiac function and prognosis in chronic heart failure patients.J Med Biochem202642780739PubTator, text miningPubMed
Coupling continuous directed evolution with base editors identifies combinatorial antibiotic resistance.Biotechnol Lett202642763377PubTator, text miningPubMed
Single-cell RNA sequencing in diabetic foot ulcers: pathogenesis, biomarkers, and translational potential.Front Clin Diabetes Healthc202642757034PubTator, text miningPubMed
CD248: Guardian of Synovial Fibroblast Fate.Arthritis Rheumatol202642703737PubTator, text miningPubMed
Immortalized smooth muscle cells enhance in vitro vasculogenesis.Angiogenesis202642622755PubTator, text miningPubMed
CD55 downregulation identifies a pathogenic CD4+ T cell axis linked to p38 MAPK signaling in rheumatoid arthritis.J Immunol202642618653PubTator, text miningPubMed
From proteome-wide Mendelian randomization and multi-omics integration to functional validation: TGFB3 as a prioritized candidate in gastric adenocarcinoma.Front Oncol202642518818PubTator, text miningPubMed
The CAFs-derived YAP1-periostin axis forms a fibrotic tumor microenvironment to promote metastatic lung tumor growth.J Transl Med202642469883PubTator, text miningPubMed
[Expression of Concern] Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma.Oncol Lett202642465859PubTator, text miningPubMed
Long-term exposure to air pollution, proteomic aging clocks, and liver-related outcomes in Chinese adults.Environ Res202642419615PubTator, text miningPubMed

1 to 10 of 1,901

See all 1,901 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/57124

GET https://conductscience.org/api/genes/v1/57124/patents?page=2